In addition to the potential differential response of MET overexpressed tumor cells to chemotherapy, changes in MET expression may be due to tumor heterogeneity in gastric cancer (34, 35), which is currently considered as a major challenge to cancer treatment. This evidence concerns the gene MET and cancer.